Bank of America’s Enliven Therapeutics ELVN Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $492K | Buy |
24,508
+4,078
| +20% | +$81.8K | ﹤0.01% | 4818 |
|
|
2025
Q1 | $402K | Sell |
20,430
-13,757
| -40% | -$271K | ﹤0.01% | 4844 |
|
|
2024
Q4 | $769K | Sell |
34,187
-14,504
| -30% | -$326K | ﹤0.01% | 4439 |
|
|
2024
Q3 | $1.24M | Buy |
48,691
+14,459
| +42% | +$369K | ﹤0.01% | 4156 |
|
|
2024
Q2 | $800K | Buy |
34,232
+17,494
| +105% | +$409K | ﹤0.01% | 4300 |
|
|
2024
Q1 | $294K | Sell |
16,738
-13,989
| -46% | -$246K | ﹤0.01% | 4849 |
|
|
2023
Q4 | $425K | Buy |
30,727
+7,621
| +33% | +$105K | ﹤0.01% | 4728 |
|
|
2023
Q3 | $316K | Buy |
23,106
+6,063
| +36% | +$82.8K | ﹤0.01% | 4785 |
|
|
2023
Q2 | $348K | Buy |
17,043
+10,498
| +160% | +$214K | ﹤0.01% | 4689 |
|
|
2023
Q1 | $143K | Buy |
6,545
+6,315
| +2,746% | +$138K | ﹤0.01% | 5314 |
|
|
2022
Q4 | $940 | Buy |
+230
| New | +$940 | ﹤0.01% | 6528 |
|
|
2022
Q1 | – | Sell |
-9,478
| Closed | -$21K | – | 7481 |
|
|
2021
Q4 | $21K | Buy |
9,478
+119
| +1% | +$264 | ﹤0.01% | 6634 |
|
|
2021
Q3 | $38K | Sell |
9,359
-6,279
| -40% | -$25.5K | ﹤0.01% | 6268 |
|
|
2021
Q2 | $124K | Sell |
15,638
-31,349
| -67% | -$249K | ﹤0.01% | 5614 |
|
|
2021
Q1 | $396K | Buy |
46,987
+44,754
| +2,004% | +$377K | ﹤0.01% | 4921 |
|
|
2020
Q4 | $49K | Buy |
2,233
+966
| +76% | +$21.2K | ﹤0.01% | 5575 |
|
|
2020
Q3 | $26K | Sell |
1,267
-7,523
| -86% | -$154K | ﹤0.01% | 5562 |
|
|
2020
Q2 | $243K | Buy |
8,790
+7,781
| +771% | +$215K | ﹤0.01% | 4572 |
|
|
2020
Q1 | $16K | Buy |
+1,009
| New | +$16K | ﹤0.01% | 5626 |
|